Product Description
For advanced solid tumors with the potential to have P-cadherin expression. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02659631)
Mechanisms of Action: P-Cadherin Inhibitor
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Small Cell Lung Cancer|Triple Negative Breast Cancer|Colorectal Cancer|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| B7831001 | P1 |
Terminated |
Non-Small-Cell Lung Cancer|Triple Negative Breast Cancer|Small Cell Lung Cancer|Colorectal Cancer |
2019-03-29 |